Adjuvant therapy after FUAS and Follow-up
To consolidate the efficacy of FUAS in the treatment of adenomyosis, three to six cycles of gonadotropin-releasing hormone agonist (GnRH-a) were suggested for patients whose uteri were greater than 10 weeks of gestation or the length of the uterine cavity were more than 9 cm. Then mirena was recommended for patients without fertility requirement when the uterus volume were suitable15. Accordingly, patients were included in FUAS group and FUAS+ (combined with GnRH-a/mirena) group based on the therapeutic regimen.
To evaluate FUAS efficacy, patients were suggested for regular follow-up. From August 2021 to December 2021, 643 patients completed the questionnaire either on the spot or by telephone if they could not come back to our cohort.